Steven L Roberds

List of Publications by Year
in descending order

54 papers	6,187 citations	186265 28 h-index	182427 51 g-index
56 all docs	56 docs citations	56 times ranked	5573 citing authors

#	Article	IF	Citations
1	Inhibition of MEK-ERK signaling reduces seizures in two mouse models of tuberous sclerosis complex. Epilepsy Research, 2022, 181, 106890.	1.6	10
2	Approach to Preventive Epilepsy Treatment in Tuberous Sclerosis Complex and Current Clinical Practice in 23 Countries. Pediatric Neurology, 2021, 115, 21-27.	2.1	13
3	Epilepsy Community at an Inflection Point: Translating Research Toward Curing the Epilepsies and Improving Patient Outcomes. Epilepsy Currents, 2021, 21, 385-388.	0.8	3
4	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatric Neurology, 2021, 123, 50-66.	2.1	230
5	Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex. Neuropharmacology, 2020, 180, 108297.	4.1	23
6	Pilot Study of Neurodevelopmental Impact of Early Epilepsy Surgery in Tuberous Sclerosis Complex. Pediatric Neurology, 2020, 109, 39-46.	2.1	23
7	Increased electroencephalography connectivity precedes epileptic spasm onset in infants with tuberous sclerosis complex. Epilepsia, 2019, 60, 1721-1732.	5.1	37
8	Tuberous Sclerosis Complex Genotypes and Developmental Phenotype. Pediatric Neurology, 2019, 96, 58-63.	2.1	21
9	Impacting development in infants with tuberous sclerosis complex: Multidisciplinary research collaboration.. American Psychologist, 2019, 74, 356-367.	4.2	9
10	The Impact of Psychiatric Symptoms on Tuberous Sclerosis Complex and Utilization of Mental Health Treatment. Pediatric Neurology, 2019, 91, 41-49.	2.1	7
11	High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex. Epilepsy Research, 2018, 148, 1-7.	1.6	25
12	Patient Voice in Rare Disease Drug Development and Endpoints. Therapeutic Innovation and Regulatory Science, 2017, 51, 257-263.	1.6	7
13	Partnering to support the next generation of epilepsy researchers. Epilepsy and Behavior, 2017, 75, 258-260.	1.7	0
14	Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference. Pediatric Neurology, 2016, 60, 1-12.	2.1	43
15	Commentary on Asato et al., â€œEpilepsy and comorbiditiesâ€”What are we waiting for?â€. Epilepsy and Behavior, 2014, 34, 136.	1.7	1
16	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 243-254.	2.1	1,185
17	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 255-265.	2.1	693
18	Discovery of Potent Inhibitors of Soluble Epoxide Hydrolase by Combinatorial Library Design and Structure-Based Virtual Screening. Journal of Medicinal Chemistry, 2011, 54, 1211-1222.	6.4	56

#	Article	IF	Citations
19	Rapid, Computer Vision-Enabled Murine Screening System Identifies Neuropharmacological Potential of Two New Mechanisms. Frontiers in Neuroscience, 2011, 5, 103.	2.8	29
20	Oral Delivery of 1,3â€Dicyclohexylurea Nanosuspension Enhances Exposure and Lowers Blood Pressure in Hypertensive Rats. Basic and Clinical Pharmacology and Toxicology, 2008, 102, 453-458.	2.5	34
21	1,3-Dicyclohexyl urea nanosuspension for intravenous steady-state delivery in rats. Journal of Experimental Nanoscience, 2007, 2, 239-250.	2.4	18
22	Circulating Succinate is Elevated in Rodent Models of Hypertension and Metabolic Disease<subtitle />. American Journal of Hypertension, 2007, 20, 1209-15.	2.0	122
23	Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment. Nanoscale Research Letters, 2007, 2, 291-296.	5.7	21
24	Exploring the Foundation of Genomics: A Northern Blot Reference set for the Comparative Analysis of Transcript Profiling Technologies. Comparative and Functional Genomics, 2004, 5, 584-595.	2.0	2
25	A cluster of novel serotonin receptor 3-like genes on human chromosome 3. Gene, 2003, 319, 137-148.	2.2	88
26	ANALYSIS OF NOVEL DISEASE-RELATED GENES IN BRONCHIAL ASTHMA. Cytokine, 2002, 19, 287-296.	3.2	181
27	BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Human Molecular Genetics, 2001, 10, 1317-1324.	2.9	644
28	Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord. Annals of Neurology, 2001, 50, 730-740.	5.3	128
29	Applying genomics tools to identify therapeutic targets for asthma. Expert Opinion on Investigational Drugs, 1998, 7, 1301-1312.	4.1	0
30	A 5â€² Dystrophin Duplication Mutation Causes Membrane Deficiency of -Dystroglycan in a Family with X-linked Cardiomyopathy. Journal of Molecular and Cellular Cardiology, 1997, 29, 3175-3188.	1.9	49
31	Immunogold localization of adhalin, Î±-dystroglycan and laminin in normal and dystrophic skeletal muscle. Biochemical Society Transactions, 1996, 24, 274S-274S.	3.4	0
32	CLINICAL AND MOLECULAR PATHOLOGICAL FEATURES OF SEVERE CHILDHOOD AUTOSOMAL RECESSIVE MUSCULAR DYSTROPHY IN SAUDI ARABIA. Developmental Medicine and Child Neurology, 1996, 38, 262-270.	2.1	12
33	The Expression of Dystrophin-associated Glycoproteins During Skeletal Muscle Degeneration and Regeneration. An Immunofluorescence Study. Journal of Neuropathology and Experimental Neurology, 1995, 54, 557-569.	1.7	22
34	Primary adhalinopathy: a common cause of autosomal recessive muscular dystrophy of variable severity. Nature Genetics, 1995, 10, 243-245.	21.4	192
35	Expression of Deletion-Containing Dystrophins in mdx Muscle: Implications for Gene Therapy and Dystrophin Function. Pediatric Research, 1995, 37, 693-700.	2.3	11
36	Non-muscle alpha-dystroglycan is involved in epithelial development.. Journal of Cell Biology, 1995, 130, 79-91.	5.2	179

#	Article	IF	Citations
37	A common missense mutation in the adhalin gene in three unrelated Brazilian families with a relatively mild form of autosomal recessive limb-girdle muscular dystrophy. Human Molecular Genetics, 1995, 4, 1163-1167.	2.9	75
38	Rapsyn may function as a link between the acetylcholine receptor and the agrin-binding dystrophin-associated glycoprotein complex. Neuron, 1995, 15, 115-126.	8.1	202
39	Adhalin mRNA and cDNA sequence are normal in the cardiomyopathic hamster. FEBS Letters, 1995, 364, 245-249.	2.8	8
40	Adhalin gene polymorphism. Human Molecular Genetics, 1994, 3, 2269-2269.	2.9	8
41	A role for dystrophin-associated glycoproteins and utrophin in agrin-induced AChR clustering. Cell, 1994, 77, 663-674.	28.9	361
42	Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell, 1994, 78, 625-633.	28.9	463
43	Î±-Dystroglycan deficiency correlates with elevated serum creatine kinase and decreased muscle contraction tension in golden retriever muscular dystrophy. FEBS Letters, 1994, 350, 173-176.	2.8	13
44	Abnormal expression of laminin suggests disturbance of sarcolemma-extracellular matrix interaction in Japanese patients with autosomal recessive muscular dystrophy deficient in adhalin.. Journal of Clinical Investigation, 1994, 94, 601-606.	8.2	27
45	Molecular Biology of the Voltage-Gated Potassium Channels of the Cardiovascular System. Journal of Cardiovascular Electrophysiology, 1993, 4, 68-80.	1.7	67
46	Chromosomal mapping in the mouse of eight K + -channel-genes representing the four Shaker -like subfamilies Shaker, Shab, Shaw , and Shal. Genomics, 1993, 18, 568-574.	2.9	34
47	Clustering and immobilization of acetylcholine receptors by the 43-kD protein: a possible role for dystrophin-related protein.. Journal of Cell Biology, 1993, 123, 729-740.	5.2	107
48	Genetic heterogeneity for Duchenne-like muscular dystrophy (DLMD) based on linkage and 50 DAG analysis. Human Molecular Genetics, 1993, 2, 1945-1947.	2.9	50
49	Heteromultimeric assembly of human potassium channels. Molecular basis of a transient outward current?. Circulation Research, 1993, 72, 1326-1336.	4.5	171
50	Developmental expression of cloned cardiac potassium channels. FEBS Letters, 1991, 284, 152-154.	2.8	41
51	Functional characterization of RK5, a voltage-gated K+channel cloned from the rat cardiovascular system. FEBS Letters, 1991, 295, 211-213.	2.8	59
52	Cloning and tissue-specific expression of five voltage-gated potassium channel cDNAs expressed in rat heart.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 1798-1802.	7.1	226
53	Effect of the antiviral compound MDL 20,610 on some aspects of murine immune function. International Journal of Immunopharmacology, 1988, 10, 639-649.	1.1	1
54	Highly degenerate, inosine-containing primers specifically amplify rare cDNA using the polymerase chain reaction. Nucleic Acids Research, 1988, 16, 10932-10932.	14.5	111